<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862635</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.257</article-id><article-id pub-id-type="other">EPP0018</article-id><article-id pub-id-type="pii">S0924933824002578</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Role of L-Arginine supplementation in Long Covid-related Fatigue and Depression in Elderly Outpatients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Moniello</surname><given-names>G.</given-names></name><xref rid="aff0447" ref-type="aff">
<sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bonfitto</surname><given-names>I.</given-names></name><xref rid="aff0448" ref-type="aff">
<sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Simonetti</surname><given-names>F.</given-names></name><xref rid="aff0449" ref-type="aff">
<sup>3</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Dimalta</surname><given-names>S.</given-names></name><xref rid="aff0448" ref-type="aff">
<sup>2</sup></xref><xref rid="cor0118" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Rizzo</surname><given-names>M. R.</given-names></name><xref rid="aff0449" ref-type="aff">
<sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bellomo</surname><given-names>A.</given-names></name><xref rid="aff0450" ref-type="aff">
<sup>4</sup></xref></contrib></contrib-group><aff id="aff0447"><sup>1</sup>Department of Geriatric Medicine and Gerontology, <institution>ASL CE</institution>, <city>Caserta</city></aff><aff id="aff0448"><sup>2</sup>Department of Mental Health, <institution>ASL FG</institution>, <city>Foggia</city></aff><aff id="aff0449"><sup>3</sup>Department of Geriatric and Internal Medicine, <institution>AOU Luigi Vanvitelli</institution>, <city>Caserta</city></aff><aff id="aff0450"><sup>4</sup>Department of Clinical and Experimental Medicine, <institution>University of Foggia</institution>, <city>Foggia</city>, <country>Italy</country></aff><author-notes><corresp id="cor0118"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="232">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S106</fpage><lpage>S106</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824002578a.pdf"/><abstract><sec id="sec0707"><title>Introduction</title><p>Chronic fatigue and psychiatric manifestations (depression, anxiety and sleep disturbances) appear to be key features of post-COVID-19 syndrome and increase significantly in prevalence over time (Lavienraj et al. J Neurol Sci 2022;434:120162). Several studies have suggested an association between altered levels of arginine metabolites and depression, anxiety and stress severity (Arisoy et al. J Psychiatr Res 2020;120:21-28). L-arginine supplementation has also been shown to improve walking performance, muscle strength, endothelial function and fatigue in adults with Long COVID (Tosato et al. Nutrients 2022;14(23):4984).</p></sec><sec id="sec0708"><title>Objectives</title><p>To study effects of L-arginine oral supplementation on chronic fatigue and depressive symptoms reported 3 months or more after acute COVID-19 onset in elderly outpatients without severe comorbid conditions.</p></sec><sec id="sec0709"><title>Methods</title><p>This is a parallel-group, double-blind, randomized controlled trial conducted on 96 over 65 non-hospitalized patients suffering from Long Covid-related fatigue and depression. The first group included patients that received 1,66 g L-arginine twice a day in addition to a standard antidepressant therapy based on Selective Serotonin Reuptake Inhibitors (SSRIs), whereas the second group received antidepressant only. Severity of fatigue and depressive symptoms was evaluated at baseline and after 8 weeks of treatment using Fatigue Symptom Inventory (FSI) and Hamilton Rating Scale for Depression (HAM-D), respectively.</p></sec><sec id="sec0710"><title>Results</title><p>At baseline, 64 patients (66,7%) reported moderate fatigue (4-6) and the remaining 32 (33,3%) reported severe fatigue (7-10). In this phase the average HAM-D score was 12,85 &#x000b1; 5,97; among patients, 57,3% experienced mild symptoms of depression, 32,3% experienced moderate symptoms and 6,4% experienced severe symptoms. After two months, patients treated with L-arginine supplementation exhibited a 30% greater improvement in fatigue-related symptom severity (p=0.008) and a significantly decrease in average HAM-D score (p=0.002) compared to the group treated with SSRI only.</p></sec><sec id="sec0711"><title>Conclusions</title><p>According to our results, adding oral L-arginine to standard antidepressant therapy in elders with Long Covid-related fatigue and depression significantly decreases severity of both physical and affective symptoms. Further studies are needed to clarify the intriguing role of L-arginine in the treatment of Post Covid-19 syndrome and its potential effects in promoting geriatric patients&#x02019; health, wellbeing and quality of life.</p></sec><sec id="sec0712"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>